维持性透析患者安全用药知信行现状调查及相关因素分析
魏珊, 纪鸥洋, 陈志豪, 黄泽慧, 李璞, 方均燕, 刘英莉

A prevalence study on knowledge, attitude, belief and practice of safe medication and analysis of related factors in dialysis patients
WEI Shan, JI Ouyang, CHEN Zhihao, HUANG Zehui, LI Pu, FANG Junyan, LIU Yingli
表2 维持性透析患者安全用药KAP得分的临床特征分析
Tab 2 Clinical characteristics analysis of KAP scores for safe medication in the maintenance dialysis patients
Indicatorn (%)

Score/

point

t/F

value

P value
Dialysis pattern-4.5120.000
MHD103 (55.08)72.26±14.61
CAPD84 (44.92)83.32±20.64
Dialysis age/month0.7480.475
<1231 (16.58)80.42±19.32
12‒2426 (13.90)79.88±21.74
>24130 (69.52)76.58±17.68
Renal anemia2.0210.045
No18 (9.63)86.00±20.97
Yes169 (90.37)76.79±18.09
Renal osteodystrophy1.4400.152
No24 (12.83)82.75±22.04
Yes163 (87.17)76.93±17.91
Hypertension0.0170.987
No23 (12.30)77.74±17.56
Yes164 (87.70)77.67±18.71
Coronary heart disease1.1780.240
No99 (52.94)79.18±19.38
Yes88 (47.06)75.99±17.48
Diabetes mellitus-0.7260.469
No134 (71.66)77.06±17.86
Yes53 (28.34)79.25±20.21